title: Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness.
abstract: Treatment of locally advanced basal cell carcinomas (laBCCs) with large, aggressive, destructive, and disfiguring tumors, or metastatic disease is challenging. Dysregulation of the Hedgehog (Hh) signaling pathway has been identified in the vast majority of basal cell carcinomas (BCCs). There are two United States Food and Drug Administration (US FDA)-approved Hh pathway inhibitors (HPIs) that exhibit antitumor activity in advanced BCC with an acceptable safety profile. Common adverse effects include muscle spasms, dysgeusia, alopecia, fatigue, nausea and weight loss.
authors: Department of Dermatology, the University of Texas McGovern Medical School at Houston, Houston, TX, USA.
authors: Sirunya
authors: S
authors: Silapunt
authors: Department of Dermatology, The University of Texas McGovern Medical School at Houston, Houston, TX, USA.
authors: Leon
authors: L
authors: Chen
authors: Departments of Dermatology and Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1452, Houston, TX 77030, USA.
authors: Michael R
authors: MR
authors: Migden
keywords: Hedgehog pathway inhibitor; basal cell carcinoma; sonidegib; vismodegib